Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
NCT ID: NCT00900016
Last Updated: 2017-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
37 participants
OBSERVATIONAL
2007-08-31
2017-06-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is assessing fibroblast activity in patients with localized pancreatic cancer undergoing surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study
NCT00100321
Studying Biomarkers in Patients With Pancreatic Cancer
NCT00900003
Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants
NCT00898482
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
NCT05287347
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
NCT00897832
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To assess the degree of fibroblast activation protein (FAP) enzymatic activity at the tumor site in patients with localized pancreatic cancer.
Secondary
* To explore correlations between tumor stromal FAP enzymatic activity and stromal α\_2-antiplasmin levels.
* To explore correlations between tumor FAP enzymatic activity and plasma dipeptidyl peptidase and plasma α\_2-antiplasmin converting enzyme activity as potential surrogates.
OUTLINE: Patients undergo fine-needle aspiration of tumor or suspected mass at baseline. Tumor samples are analyzed by IHC for fibroblast activation protein (FAP) expression, immunocapture assay for ex vivo FAP enzymatic activity, and western analysis for FAP concentrations. Blood samples are collected weekly and analyzed for dipeptidyl peptidase activity by ELISA and α\_2-antiplasmin converting enzyme.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
protein expression analysis
western blotting
immunohistochemistry staining method
immunologic technique
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Biopsy-proven adenocarcinoma of the pancreas or pancreatic mass suspicious for pancreatic cancer
* Localized disease
* Scheduled to undergo a resection or exploration of their pancreatic tumor
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Fox Chase Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven Cohen, MD
Role: PRINCIPAL_INVESTIGATOR
Fox Chase Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-011
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000579635
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.